[1] CHEN D S, MELLMAN I. Elements of cancer immunity and the cancer-immune set point. Nature, 2017,541(7637):321-330.
[2] HUANG Y, LIANG D, LIU J, et al. The breakthroughs in cancer immune checkpoint based therapy: areview of development in immune checkpoint study and its application. Comb Chem High Throughput Screen, 2017, 20(5):430-439.
[3] ROSENBAUM L. Tragedy, perseverance, and chance-the story of CAR-T therapy. N Engl J Med, 2017,377(14):1313-1315.
[4] QUINTAS-CARDAMA A. CAR T-cell therapy in large B-cell lymphoma. N Engl J Med, 2018,378(11):1065.
[5] SPAIN L, DIEM S, LARKIN J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev, 2016, 44: 51-60.
[6] HEINZERLING L, OTT P, HODI F, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer, 2016,4: 50.
[7] SCHUBERT M, HOFFMANN J, DREGER P, et al. Chimeric antigen receptor transduced T cells: tuning up for the next generation. Int J Cancer, 2017, 142(9):1738-1747.
[8] DE FRANCESCO L. CAR-T cell therapy seeks strategies to harness cytokine storm. Nat Biotechnol, 2014, 32(7):604.
[9] LJUNGGREN H G, MALMBERG K J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol, 2007,7(5):329-339.
[10] MORVAN M G, LANIER L L. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer, 2016, 16(1):7-19.
[11] VIVIER E, RAULET D H, MORETTA A, et al. Innate or adaptive immunity? The example of natural killer cells. Science, 2011,331(6013):44-49.
[12] BORDON Y. Innate lymphoid cells: on the origin of ILCs. Nat Rev Immunol, 2014, 14(3):133.
[13] NATARAJAN K, DIMASI N, WANG J, et al. Structure and function of natural killer cell receptors: multiple molecular solutions to self, nonself discrimination. Annu Rev Immunol, 2002, 20: 853-885.
[14] SUN J C, BEILKE J N, LANIER L L. Adaptive immune features of natural killer cells. Nature, 2009, 457(7229):557-561.
[15] LONG E O, KIM H S, LIU D, et al. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol, 2013, 31: 227-258.
[16] MARTINET L, SMYTH M J. Balancing natural killer cell activation through paired receptors. Nat Rev Immunol, 2015, 15(4):243-254.
[17] MORETTA A, BOTTINO C, VITALE M, et al. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol, 1996, 14: 619-648.
[18] DENG W, GOWEN B G, ZHANG L, et al. Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science, 2015, 348(6230):136-139.
[19] RAULET D H, GASSER S, GOWEN B G, et al. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol, 2013, 31: 413-441.
[20] RAULET D H. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol, 2003, 3(10):781-790.
[21] ALVAREZ-BRECKENRIDGE C A, YU J, PRICE R, et al. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med, 2012, 18(12):1827-1834.
[22] PENDE D, BOTTINO C, CASTRICONI R, et al. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol Immunol, 2005, 42(4):463-469.
[23] CHILDS R W, CARLSTEN M. Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nat Rev Drug Discov, 2015, 14(7):487-498.
[24] FERGUSON F, GRAY N. Kinase inhibitors: the road ahead. Nat Rev Drug Discov, 2018,17(5):353-377.
[25] HASSOLD N, SEYSTAHL K, KEMPF K, et al. Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib. Int J Cancer, 2012, 131(6):916-927.
[26] SALIH J, HILPERT J, PLACKE T, et al. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int J Cancer, 2010,127(9):2119-2128.
[27] KIM H, KIM S H, KIM M J, et al. EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells. J Immunother, 2011, 34(4):372-381.
[28] YEUNG D T, TANG C, VIDOVIC L, et al. KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy. Blood, 2015, 126(25):2720-2723.
[29] SOPPER S, MUSTJOKI S, GJERTSEN B T, et al. NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib. Leukemia, 2017, 31(10):2264-2267.
[30] HUANG Y, WANG Y, LI Y, et al. Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2. J Cancer Res Clin Oncol, 2011, 137(5):829-837.
[31] SPRINZL M F, REISINFER F, PUSCHNIK A, et al. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology, 2013, 57(6):2358-2368.
[32] ROMERO A I, CHAPUT N, POIRIER-COLAME V, et al. Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Ralpha and NKG2D triggering. Cancer Res, 2014, 74(1):68-80.
[33] FALKENBERG K, JOHNSTONE R. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov, 2014, 13(9):673-691.
[34] SATWANI P, BAVISHI S, SAHA A, et al. Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity. Cytotherapy, 2014, 16(10):1431-1440.
[35] SHI J, TRICOT G J, GARG T K, et al. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood, 2008, 111(3):1309-1317.
[36] LUNDQVIST A, YOKOYAMA H, SMITH A, et al. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood, 2009, 113(24):6120-6127.
[37] HU W, ZHENG R R, CUI H X, et al. Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity. Asian J Androl, 2012, 14(5):695-702.
[38] JARDINE L, HAMBLETON S, BIGLEY V, et al. Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands. Leuk Lymphoma, 2013, 54(1):167-173.
[39] ZHANG C, WANG Y, ZHOU Z, et al. Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol Immunother, 2009, 58(8):1275-1285.
[40] CHU E, CALLENDER M A, FARRELL M P, et al. Thymidylate synthase inhibitors as anticancer agents: from bench to bedside. Cancer Chemother Pharmacol, 2003, 52(suppl 1):80-89.
[41] AKETA H, TATSUMI T, KOHGA K, et al. The combination therapy of alpha-galactosylceramide and 5-fluorouracil showed antitumor effect synergistically against liver tumor in mice. Int J Cancer, 2013, 133(5):1126-1134.
[42] ZHAO L, WANG W J, ZHANG J N, et al. 5-Fluorouracil and interleukin-2 immunochemotherapy enhances immunogenicity of non-small cell lung cancer A549 cells through upregulation of NKG2D ligands. Asian Pac J Cancer Prev, 2014, 15(9):4039-4044.
[43] SCHMIEDEL B J, ARELIN V, GRUENEBACH F, et al. Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation. Int J Cancer, 2011, 128(12):2911-2922.
[44] CANY J, ROEVEN M, HOOGSTAD-VAN E J, et al. Decitabine enhances targeting of AML cells by CD34(+) progenitor-derived NK cells in NOD/SCID/IL2Rg(null) mice. Blood, 2018, 131(2):202-214.
[45] MORISAKI T, ONISHI H, KOYA N, et al. Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via the NKG2D-MICA/B system. Anticancer Res, 2011, 31(7):2505-2510.
[46] SIENA L, PACE E, FERRARO M, et al. Gemcitabine sensitizes lung cancer cells to Fas/FasL system-mediated killing. Immunology, 2014, 141(2):242-255.
[47] WENNERHERG E, SARHAN D, CARLSTEN M, et al. Doxorubicin sensitizes human tumor cells to NK cell-and T-cell-mediated killing by augmented TRAIL receptor signaling. Int J Cancer, 2013, 133(7):1643-1652.
[48] BAE J H, KIM J Y, KIM M J, et al. Quercetin enhances susceptibility to NK cell-mediated lysis of tumor cells through induction of NKG2D ligands and suppression of HSP70. J Immunother, 2010, 33(4):391-401.
[49] KIM J H, LEE J K. Naringenin enhances NK cell lysis activity by increasing the expression of NKG2D ligands on Burkitt′s lymphoma cells. Arch Pharm Res, 2015, 38(11):2042-2048.
[50] KIM J H, LEE J K. Sesamolin enhances NK cell lysis activity by increasing the expression of NKG2D ligands on Burkitt′s lymphoma cells. Int Immunopharmacol, 2015, 28(2):977-984.
[51] KUMAR S, TOMAR M S, ACHARYA A. Chelerythrine delayed tumor growth and increased survival duration of Dalton′s lymphoma bearing BALB/c H(2d) mice by activation of NK cells in vivo. J Cancer Res Ther, 2015, 11(4):904-910.
[52] YAO C, NI Z, GONG C, et al. Rocaglamide enhances NK cell-mediated killing of non-small cell lung cancer cells by inhibiting autophagy. Autophagy, 2018, 14(10):1831-1844.
[53] SIEW Y Y, NEO S Y, YEW H C, et al. Oxaliplatin regulates expression of stress ligands in ovarian cancer cells and modulates their susceptibility to natural killer cell-mediated cytotoxicity. Int Immunol, 2015, 27(12):621-632.
[54] AMIN P J, SHANKAR B S. Sulforaphane induces ROS mediated induction of NKG2D ligands in human cancer cell lines and enhances susceptibility to NK cell mediated lysis. Life Sci, 2015, 126: 19-27.
[55] FERNANDEZ L, VALENTIN J, ZALACAIN M, et al. Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner. Cancer Lett, 2015, 368(1):54-63.
[56] LEUNG W H, VONG Q P, LIN W, et al. Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRgamma activation. J Exp Med, 2013, 210(12):2675-2692.
[57] KIM S J, HA G H, BAE J H, et al. COX-2-and endoplasmic reticulum stress-independent induction of ULBP-1 and enhancement of sensitivity to NK cell-mediated cytotoxicity by celecoxib in colon cancer cells. Exp Cell Res, 2015, 330(2):451-459.
[58] SRIVASTAVA R M, LEE S C, ANDRADE F P, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res, 2013, 19(7):1858-1872.
[59] MIN D, LU X B, WANG X, et al. Downregulation of miR-302c and miR-520c by 1,25(OH)2D3 treatment enhances the susceptibility of tumour cells to natural killer cell-mediated cytotoxicity. Br J Cancer, 2013, 109(3):723-730.
[60] FIONDA C, MALGARINI G, SORIANI A, et al. Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3. J Immunol, 2013, 190(12):6662-6672.
[61] LAI H C, CHANG C J, YANG C H, et al. Activation of NK cell cytotoxicity by the natural compound 2,3-butanediol. J Leukoc Biol, 2012, 92(4):807-814.
[62] SAND K L, KNUDSEN E, ROLIN J, et al. Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate. Cell Mol Life Sci, 2009, 66(8):1446-1456.
[63] CHU M, XU L, ZHANG M B, et al. Role of baicalin in anti-influenza virus as a potent inducer of IFN-Gamma. Biomed Res Int, 2015(5):1-11.
[64] GUO Y, FENG X, JIANG Y, et al. PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells. Oncotarget, 2016,7(30):48360-48374.
[65] CHEN H, ZHIDAN W, XIA R, et al. Scorpion venom activates natural killer cells in hepatocellular carcinoma via the NKG2D-MICA pathway. Int Immunopharmacol, 2016,35: 307-314.
[66] LIAN G Y, WANG Q M, TANG P M, et al. Combination of asiatic acid and naringenin modulates NK cell anti-cancer immunity by rebalancing Smad3/Smad7 signaling. Mol Ther, 2018, 26(9):2255-2266.